Nonagon receives FDA clearance for OTC remote examination platform
Nonagon, a medical device company based in Israel and the U.S., has received FDA clearance to sell its N9+ device as an over-the-counter product, making remote patient examinations more accessible, the company said.
The Nonagon N9+ device allows for clinical-grade remote examinations of various health parameters, including the heart, lungs, abdomen, oxygen saturation, ears, mouth/throat, skin and body temperature. The device automatically documents and shares exam results with physicians via telehealth, potentially contributing to better patient care and outcomes.
[Read more: CVS using technology to fill prescriptions remotely]
"We are thrilled to receive FDA clearance for the Nonagon N9+ device, which brings us one step closer to our mission of making remote digital medicine clinically reliable and accessible to the community," said Alon Natanson, CEO of Nonagon. "This clearance allows us to offer a cutting edge solution that empowers patients to proactively manage their health and enhances the capabilities of healthcare providers to remotely monitor and diagnose patients."
The Nonagon N9+ device will soon be available on the company's website in June 2023, with plans to launch it in broader distribution shortly after that. With its user-friendly interface and advanced features, the Nonagon N9+ device is poised to revolutionize the healthcare industry by reducing unnecessary in-person visits and possibly improving health outcomes, the company said.